REDUCING OPIOID OVERDOSE, MISUSE AND DEPENDENCY

A GUIDE FOR CCOs

Oregon Health Authority
October 6, 2015
Reducing Opioid Overdose, Misuse and Dependency: A Guide for CCOs

Although opioids have a place in treating patients, health care prescribing of opioids for pain has generated an epidemic of prescription drug overdose mortality and morbidity, as well as substance use disorder and unstable pain care over the last fifteen years. In fact, drug overdose has surpassed motor vehicle crashes as a cause of death in Oregon and the US.

This guide is a resource to help CCOs develop a comprehensive approach to reducing opioid overdose, misuse, and opioid use disorder. CCOs play an important role in helping their members/patients manage pain while minimizing the risk of adverse effects due to opioid use.

Things to consider:

- Use of opioids for long-term management of chronic non-cancer pain lacks evidence of benefits, and may lead to poor results and negative side effects
- The risk of adverse outcomes, including death, increase with co-prescribing, especially with opioid/benzodiazepine combinations
- Research in pain management using alternative therapies has shown good results for management of chronic non-cancer pain
- Medication assisted treatment (such as buprenorphine and naltrexone) prescribed for opioid use disorder can stabilize patients and improve social functioning
- Naloxone is effective in reversing overdose when co-prescribed with opioids and/or used in community based lay rescue
- Prescription Drug Monitoring provides prescribers and pharmacies with information on patient Rx history, which may identify drug seeking, patient safety or patients at risk for opioid use disorder.

The strategies outlined in the following pages are considered promising practices and interventions to help reduce the epidemic of adverse effects associated with opioid use, and should not replace clinical judgment by clinicians. CCOs are encouraged to work with internal and external partners, including administrators, quality improvement staff, clinicians, hospitals, epidemiologists, researchers, clinical advisory panels, local health departments, and pain guidance groups.

**STATE CONTACTS:**
Katrina Hedberg, MD, MPH
Health Officer
Oregon Health Authority
971.673.0435
Katrina.Hedberg@state.or.us

Lisa Millet
Manager
Injury and Violence prevention Program
Oregon Health Authority
971.673.1059
Lisa.M.Millet@state.or.us
Strategy: Use Opioid Prescribing Guidelines for Pain Management

Reducing the risk of prescription opioid overdose and misuse begins in the clinic. Starting patients on opioids presents a substantial risk of long-term use, so careful consideration of how patients are selected and managed for opioid treatment is important. A five step approach to treating patients with chronic complex non-cancer pain is described in the model Oregon Opioid Prescribers Guidelines developed by the (Southern) Oregon Pain Guidance Group (www.oregonpainguidance.com/opioid-prescribing-guidelines-2/introduction/). The five steps include:

- Practice assessment: standard clinic policies should be established around chronic pain treatment
- Patient assessment: risk assessments help determine whether opioids are appropriate for a patient
- Non-opioid treatment: chronic pain treatment is best started with non-opioid treatments with functional goals in mind
- Patient reassessment: following non-opioid treatment, if low-dose opioid treatment may benefit a patient, patients must be informed of opioid risks and benefits
- Follow-up visits: pain treatment is a process. Providers should periodically follow up with patients to assess safety and progress toward treatment goals.

The guidelines include:

- Assessment tools and flowcharts for treatment management
- Aberrancy screening tools
- Patient/provider communication tools (e.g. treatment agreements)
- Guidelines to non-opioid treatment options
- Tapering guidelines
- Guidelines on handling special issues (e.g. managing patients on opioids and benzodiazepines; handling difficult conversations with patients)

CCOs are strongly encouraged to implement prescribing guidelines in clinical settings, encourage and incentivize contract providers to implement the prescribing guidelines, and develop policies to assure use among prescribers.

Resources:

Strategy: Use Opioid Prescribing Guidelines in Emergency Departments

Prescribing opioids to patients in emergency departments (EDs) can pose unique challenges. While pain relief is important when a person needs emergency care, treating pain is a complex process. Prescribing guidelines for opioids were developed by The Oregon Chapter of the American College of Emergency Physicians (OCEP) (http://www.ocep.org/images/pdf/ed_opioid_abuse_guidelines.pdf), and include important facets of prescribing opioids in the context of EDs. Some features of the ED guideline recommendations:

- To the extent possible, one medical provider should provide all opioids to treat a patient’s chronic pain
- Administration of intravenous and intramuscular opioids in the ED for the relief of acute exacerbations of chronic pain is discouraged
- Emergency medical providers (EMPs) should not provide replacement prescriptions for controlled substances that were lost, destroyed or stolen
- EMPs should not provide replacement doses of methadone for patients in a methadone treatment program
- Long-acting or controlled-release opioids (e.g., OxyContin®, fentanyl patches and methadone) should not be prescribed in EDs
- Access the Oregon Prescription Drug Monitoring Program online, before prescribing any controlled substances
- EDs should perform screening, brief interventions and treatment referrals for patients with suspected prescription opiate abuse (see SBIRT link below)
- Prescriptions for opioid pain medication from the ED for acute injuries, such as fractured bones, should be in an amount that will last until the patient is reasonably able to receive follow up care for the injury. In most cases, this should not exceed 7 day supply.

CCOs are encouraged to review the entire Guidelines and engage EDs and providers in utilizing the Guidelines in practice.

Resources:


Oregon SBIRT: http://www.sbirtoregon.org/

http://www.oregon.gov/oha/amh/Pages/sbirt.aspx
Strategy: Use the Oregon Prescription Drug Monitoring Program to Assess and Manage

The Oregon Prescription Drug Monitoring Program (PDMP) operates a web-based data system that contains information on controlled prescription medications dispensed by Oregon licensed retail pharmacies. Pharmacies are required by law to submit data 72 hours after a prescription is dispensed for all Schedule II – IV controlled substances dispensed. Controlled substances reported include opioids, sedative hypnotics, benzodiazepines, stimulants, and other drugs. The PDMP has been in operation since 2011.

The primary purpose of the PDMP is to provide practitioners and pharmacists a tool to improve health care and patient safety. Authorized system users (which can include provider delegates such as clinical office staff) can logon to the PDMP web-based system and request a report of the controlled substance medications dispensed to their patients. Prescription records include information on the dispenser, prescriber, and name and quantity of drug.

What role does the PDMP play in reducing opioid overdose? The Oregon PDMP is a critical component of assessment and management before and during pain treatment. Providers and their delegates can check the PDMP when seeing new patients, when writing a new or renewal of a prescription for a controlled substance, periodically monitor the prescription history and use of their patients, identify problematic or inappropriate prescription access and use, use information from the patient report to coordinate care with other prescribers identified in the report, and use the PDMP in conjunction with Opioid Prescribers Guidelines to better manage patient pain treatment.

Resources:

PDMP web portal (user access and registration): www.orpdmp.com/

How to register for the PDMP: http://www.orpdmp.com/orpdmpfiles/PDF_Files/Leaflets/HowToRegister.pdf

How to look up information (for registered users):
http://www.orpdmp.com/orpdmpfiles/PDF_Files/Leaflets/HowToQuerypdf
Strategy: Provide Coverage for Non-Opioid Chronic non-Cancer Pain Treatment Therapies

Opioids may lack efficacy in relieving chronic non-cancer pain long-term, and are inferior to sleep restoration, manipulation therapy, acupuncture, massage, mindfulness training/CBT, and physical exercise in providing long-term benefit to patients. Unfortunately, because alternative therapies may not be covered under private and public health insurance plans, many people do not have access to non-pharmacological pain management options.

Chronic non-cancer pain is different that acute pain and often requires different interventions than acute pain, including pain rehabilitation through multidisciplinary teams. Multi-disciplinary teams should consist of two or more professions working collaboratively to meet patients’ needs. CCOs are encouraged to review policies around providing coverage for non-pharmacological pain management and evaluate how pain management practices and policies (especially around complex chronic non-cancer pain) may impact their client/patient populations. For example, on January 1, 2016, the Oregon Health Plan will begin providing reimbursement for multimodal pain care for conditions of the back and spine, including for low back pain. The Health Evidence Review Commission recommends assessing patients with back pain using a validated assessment tool (e.g. STarT Back Assessment Tool1) to determine their risk level for developing chronic pain.

Resources:


1 STaRT Back is an evidence-based systematic approach to assessment and decision making for the treatment of patients with back pain. Information can be found at http://www.keele.ac.uk/sbst/startbacktool/
Strategy: Co-Prescribe Naloxone When Prescribing Opioids for At-Risk Patients

Naloxone is the antidote for opioid overdose—it saves lives. Naloxone is not a controlled substance-- it can be prescribed by any health care provider with a medical license. The drug has been used for decades to reverse overdose associated with opioids. In fact, naloxone “rescue” programs are emerging among first responder organizations, such as emergency medical services, law enforcement agencies, and public health needle exchange programs. Naloxone can be prescribed to patients for use in an overdose emergency, and Oregon law allows naloxone to be prescribed to third party individuals who may witness a friend’s or relative’s overdose (not unlike epinephrine for emergency use by lay people). CCOs can support the practice of co-prescribing naloxone by providers, and can review policies that make it easier for providers to co-prescribe.

Reasons to prescribe naloxone may include (but are not limited to):

- Patient has a history of opioid intoxication or overdose
- Patient has a suspected history of substance abuse or non-medical opioid use
- Patient is on a high dose (> 50 mg morphine equivalent per day)
- Patient is starting on methadone or buprenorphine for addiction
- Patient starting on an opioid and one or more of the following applies:
  - has a history of smoking, COPD, asthma, emphysema, sleep apnea, respiratory illness
  - has a concurrent benzodiazepine (or other sedative) prescription
  - has a concurrent antidepressant prescription
  - has a history of HIV/AIDS, renal dysfunction, cardiac illness, hepatic illness
  - Alcohol use or abuse is suspected

Providers can discuss an emergency overdose plan with patients when prescribing naloxone.

Resources:

Prescribe to Prevent: http://prescribetoprevent.org/prescribers/palliative/

OHA naloxone training:
Strategy: Provide Medication Assisted Treatment for Opioid Use Disorder

Some patients develop opioid use disorders (i.e. dependence) when prescribed opioids for pain treatment. Medication assisted treatment (MAT) is an approach to the treatment of substance use disorders that uses agonist, partial agonist and antagonist medications (e.g. buprenorphine, methadone and naltrexone) along with counseling and behavioral therapies. The combination of MAT and behavioral therapies is an evidenced-based practice for treating opioid use disorder. MAT can help sustain recovery and improve social functioning for some people struggling with opioid use disorder.

Despite proven effectiveness as a treatment adjunct, MAT utilization in primary care and community treatment settings is low, and in Oregon, outside of 15 opioid treatment programs (OTPs), MAT is available in few locations. Reasons for low rates of adoption in primary care may include a lack of staff understanding of the MAT medications, organizational philosophies or staff perceptions about use of these medications, the cost of medications, lack of coordination with community based opioid use disorder treatment for detoxification and stabilization of patients, lack of coordination with mental health providers for cognitive therapies, or lack of trained qualified providers to oversee this treatment (especially in the use of buprenorphine to treat opioid use disorders).

With recent and ongoing changes in health care systems in Oregon, opportunities exist for providers to integrate MAT into primary care and in substance use disorder treatment. Offering a full range of effective and coordinated treatments options, including medications and evidence-based behavioral treatment programs, can result in improved treatment outcomes among patients struggling with opioid use disorders. MAT can and should be coordinated with other support strategies that focus on recovery and improving cognitive, and social functioning. In fact, these treatment approaches share the same goals while also addressing the biological issues related to opioid use disorder.

Resources:

SAMHSA, Medication-Assisted Treatment website: http://www.samhsa.gov/medication-assisted-treatment

MAT overview: www.integration.samhsa.gov/clinical-practice/mat/mat-overview#implement

MAT implementation checklist: www.integration.samhsa.gov/clinical-practice/mat/MAT_Implementation_Checklist_FINAL.pdf